Friday, April 28, 2023 1:29:25 PM
MCRB Perverse mkt action now. Candidate passed PDUFA and has great mkt potential. Rollout in June.
MCRB is partners with Nestle and many looking to an outright buyout.
Another candidate coming up in May.
I will hold and wait for eventual payday.
MCRB is partners with Nestle and many looking to an outright buyout.
Another candidate coming up in May.
I will hold and wait for eventual payday.
Recent MCRB News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:10:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:05:17 PM
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- Seres Therapeutics to Present at CARB-X Investor Day • GlobeNewswire Inc. • 04/09/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 08:50:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:42:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 11:05:27 AM
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/12/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 10:39:08 PM
- Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:05 PM
- Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases • GlobeNewswire Inc. • 02/12/2026 12:00:00 PM
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy • GlobeNewswire Inc. • 01/06/2026 12:00:00 PM
- Seres Therapeutics to Participate in Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 03:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:05:23 PM
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 • GlobeNewswire Inc. • 10/30/2025 11:00:00 AM
- Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 • GlobeNewswire Inc. • 10/29/2025 11:00:00 AM
